California institute for regenerative medicine awards funding for car-t nxc-201 u.s. al amyloidosis clinical trial (nexicart-2)

$8 million grant funds development of nxc-201 in relapsed/refractory al amyloidosis $8 million grant funds development of nxc-201 in relapsed/refractory al amyloidosis

CAR Ratings Summary

CAR Quant Ranking